Studies on TREM2, a receptor thought to contribute to the DAM phenotype, have shown opposing outcomes where its depletion results in improved or worsened disease in PS19 (tauopathy) and 5xFAD (amyloidosis) Alzheimer’s disease (AD) mouse models, respectively [27,28]. The gene discussed is TREM2; the disease is amyloidosis.